A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma
- 153 Downloads
Preclinical models showed TAC-101 (4-[3,5-bis(trimethylsilyl) benzamide] benzoic acid), an oral synthetic retinoid, has anti-tumor activity in hepatocellular carcinoma (HCC). A phase I/II study was performed in advanced HCC patients (pts).
Patients and methods
Thirty-three patients were enrolled. During Phase I, pts received 40 mg daily for 14 days q3 weeks; 2 of 5 patients developed DLT so dose was reduced to 20 mg/day. Twenty-eight patients received 20 mg/day.
No pt had a CR or PR, but 12 of 21 (57%) had SD. Two pts (9.5%) had late PR after discontinuing TAC-101. Median survival (MS) for all 28 pts treated with 20 mg/day was 12.7 months (95% CI 8.8–22.7); MS for 21 evaluable pts was 19.2 months (95% CI 10.4–27.6).
20 mg of TAC- was well tolerated. Significant disease stabilization (12/21 pts, 57%), 2 late PRs, and prolonged MS (19.2 months) suggest that TAC-101 provides meaningful patient benefit.
KeywordsHepatocellular carcinoma Clinical trial Retinoids TAC-101 Survival
- Llovet JM, Ricci S, Mazzaferro V et al (2007) Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): results of a Phase III randomized placebo-controlled trials (SHARP trial). American Society of Clinical Oncology Annual Meeting, ChicagoGoogle Scholar
- Posey J, Johnson P, Mok T, Hirmand M, Dahlberg S, Kwei L, Leung T (2005) Results of a phase 2/3 open-label, randomized trial of T138067 versus doxorubicin (DOX) in chemotherapy-naive, unresectable hepatocelular carcinoma (HC). 2005 ASCO Annual Meeting, Orlando, FL, USAGoogle Scholar
- Sankaranarayanan, Mathew RB (1996) Retinoids as cancer-preventive agents. IARC Sci Publ (139):47–59Google Scholar
- Ventegodt S, Morad M, Hyam E, Merrick J (2004) Clinical holistic medicine: induction of spontaneous remission of cancer by recovery of the human character and the purpose of life (the life mission). Sci World J 4:362–377Google Scholar
- Yoshimura K, Uchida G, Okazaki M et al (2003) Differential expression of heparin-binding EGF-like growth factor (HB-EGF) mRNA in normal human keratinocytes induced by a variety of natural and synthetic retinoids. Exp Cell Res 12(S2):28–34Google Scholar